Home › Funds › GENERAL ATLANTIC, L.P. › PBLS
GENERAL ATLANTIC, L.P. position in PBLS
PARABILIS MEDICINES INC · Health Care
GENERAL ATLANTIC, L.P. reported holding 1,538,461 shares of PBLS (PARABILIS MEDICINES INC) in its Q3 2026 13F filing — a position valued at US$49.7M, representing 2.04% of its reported portfolio and ranking #10 among its reported holdings. GENERAL ATLANTIC, L.P. has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How GENERAL ATLANTIC, L.P.'s PBLS position evolved
GENERAL ATLANTIC, L.P. first disclosed a stake in PBLS in Q2 2026 at 1,538,461 shares (US$42.1M). The position peaked in Q3 2026 at 1,538,461 shares, worth US$49.7M. Across 2 filings, GENERAL ATLANTIC, L.P. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1,538,461 shares valued at US$49.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.54M | $42.11M | New |
| Q3 2026 | 1.54M | $49.68M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PBLS and 13F data
PBLS (PARABILIS MEDICINES INC) is a Health Care company. 121 other funds we track also report a position in PBLS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$791.9M), ARCH Venture Management, LLC (US$175.5M), Alphabet Inc. (US$158.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PBLS
- RA CAPITAL MANAGEMENT, L.P. 28.93M sh · $791.91M · Q2 2026
- ARCH Venture Management, LLC 6.41M sh · $175.52M · Q2 2026
- Alphabet Inc. 4.92M sh · $158.85M · Q3 2026
- venBio Partners LLC 5.27M sh · $144.15M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 4.17M sh · $134.54M · Q3 2026
- Nextech Invest Ltd. 4.66M sh · $127.63M · Q2 2026
- Cormorant Asset Management, LP 4.62M sh · $126.33M · Q2 2026
- Siren, L.L.C. 2.99M sh · $96.62M · Q3 2026
- Farallon Capital Management 2.37M sh · $64.82M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.37M sh · $64.82M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.92M sh · $52.57M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.88M sh · $51.47M · Q2 2026
More on GENERAL ATLANTIC, L.P.
FAQ
How long has GENERAL ATLANTIC, L.P. held PBLS?
GENERAL ATLANTIC, L.P. has disclosed PBLS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is GENERAL ATLANTIC, L.P.'s current position in PBLS?
As of Q3 2026, GENERAL ATLANTIC, L.P. holds 1.54M shares of PBLS (PARABILIS MEDICINES INC), valued at $49.68M, representing 2.04% of its reported portfolio and ranking #10.
Has GENERAL ATLANTIC, L.P. been buying or selling PBLS?
In the latest 13F filing (Q3 2026), GENERAL ATLANTIC, L.P. held unchanged its position in PBLS. The position peaked in Q3 2026 at 1.54M shares.
Which other funds hold PBLS?
Other major institutional holders of PBLS include RA CAPITAL MANAGEMENT, L.P., ARCH Venture Management, LLC, Alphabet Inc., among 121 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.